Security key
N62509117
NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW)
CUSIP: N62509117
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / *W EXP 99/99/999
- Total 13F shares
- 1,298,188
- Total 13F value
- $29,913,961
- Share change
- -1,325
- SEC-reported price per share
- $23.00
- Number of holders
- 9
- Value change
- +$102,808
- Number of buys
- 1
- Number of sells
- 4
Report period
Q4 2025
Institutions
9
Top holders
9
NAMSW full security history
Ownership snapshot
Full 13F holder table
NewAmsterdam Pharma Co N.V. SEC filings
NewAmsterdam Pharma Co N.V. company facts
Broader feeds
Ownership snapshot
Top reported holders of NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
3/15
Latest evidence
30 Sep 2025
13F
13D/G
3/4/5
Lead comparable stake: 9.9%
12 rows are not safely comparable across share classes.
13D/G row: RA CAPITAL MANAGEMENT, L.P.
Showing 1-6 of 15 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 9.9%.
3 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership
Top 3
RA CAPITAL MANAGEMENT, L.P.
9.9%
Forbion Capital Fund IV Cooperati...
8.3%
VIKING GLOBAL INVESTORS LP
3.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
9.9%
Reported 13D/G
· 31 Mar 2025
|
$294,054,725
10,472,271 shares
mixed-class rows
|
— | 30 Sep 2025 |
| Forbion Capital Fund IV Cooperatief U.A. |
13D/G
ForGrowth NAP B.V.
|
8.3%
Reported 13D/G
· 26 Sep 2025
|
$223,140,090
9,316,914 shares
|
-$30,222,313 | 26 Sep 2025 |
| VIKING GLOBAL INVESTORS LP |
13F
13D/G
Company
|
3.7%
Reported 13D/G
· 31 Dec 2025
|
$184,164,187
6,475,534 shares
|
— | 30 Sep 2025 |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
Company · 10%+ Owner
|
—
mixed-class rows
|
$306,562,488
10,819,110 shares
mixed-class rows
|
— | 30 Sep 2025 |
| ForGrowth NAP B.V. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$272,125,599
10,656,172 shares
|
— | 30 Dec 2024 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
—
mixed-class rows
|
$483,564,327
17,202,289 shares
mixed-class rows
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
9
Shares
1,298,188
Rows available
9
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
9
Q4 2025 holders
9
Holder diff
0
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|